199 related articles for article (PubMed ID: 11489947)
1. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).
Di Cristofano A; Niki M; Zhao M; Karnell FG; Clarkson B; Pear WS; Van Aelst L; Pandolfi PP
J Exp Med; 2001 Aug; 194(3):275-84. PubMed ID: 11489947
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity.
Kashige N; Carpino N; Kobayashi R
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2093-8. PubMed ID: 10688886
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.
Di Cristofano A; Carpino N; Dunant N; Friedland G; Kobayashi R; Strife A; Wisniewski D; Clarkson B; Pandolfi PP; Resh MD
J Biol Chem; 1998 Feb; 273(9):4827-30. PubMed ID: 9478921
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation.
Zhao M; Schmitz AA; Qin Y; Di Cristofano A; Pandolfi PP; Van Aelst L
J Exp Med; 2001 Aug; 194(3):265-74. PubMed ID: 11489946
[TBL] [Abstract][Full Text] [Related]
5. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.
Carpino N; Wisniewski D; Strife A; Marshak D; Kobayashi R; Stillman B; Clarkson B
Cell; 1997 Jan; 88(2):197-204. PubMed ID: 9008160
[TBL] [Abstract][Full Text] [Related]
6. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
Bhat A; Johnson KJ; Oda T; Corbin AS; Druker BJ
J Biol Chem; 1998 Nov; 273(48):32360-8. PubMed ID: 9822717
[TBL] [Abstract][Full Text] [Related]
7. Role of Dok-1 and Dok-2 in leukemia suppression.
Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
[TBL] [Abstract][Full Text] [Related]
8. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.
Yasuda T; Shirakata M; Iwama A; Ishii A; Ebihara Y; Osawa M; Honda K; Shinohara H; Sudo K; Tsuji K; Nakauchi H; Iwakura Y; Hirai H; Oda H; Yamamoto T; Yamanashi Y
J Exp Med; 2004 Dec; 200(12):1681-7. PubMed ID: 15611294
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel member of the DOK family that binds and modulates Abl signaling.
Cong F; Yuan B; Goff SP
Mol Cell Biol; 1999 Dec; 19(12):8314-25. PubMed ID: 10567556
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK
Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916
[TBL] [Abstract][Full Text] [Related]
11. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
12. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.
Janas JA; Van Aelst L
Mol Cell Biol; 2011 Jul; 31(13):2552-65. PubMed ID: 21536658
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
Hickey FB; England K; Cotter TG
J Leukoc Biol; 2005 Jul; 78(1):289-300. PubMed ID: 15857938
[TBL] [Abstract][Full Text] [Related]
16. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
17. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
18. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
19. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
Shi CS; Tuscano JM; Witte ON; Kehrl JH
Blood; 1999 Feb; 93(4):1338-45. PubMed ID: 9949177
[TBL] [Abstract][Full Text] [Related]
20. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
